Zheng Hongmei, Siddharth Sumit, Parida Sheetal, Wu Xinhong, Sharma Dipali
Hubei Provincial Clinical Research Center for Breast Cancer, Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China.
The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.
Cancers (Basel). 2021 Jul 4;13(13):3357. doi: 10.3390/cancers13133357.
Triple negative breast cancer (TNBC) is a heterogeneous disease and is highly related to immunomodulation. As we know, the most effective approach to treat TNBC so far is still chemotherapy. Chemotherapy can induce immunogenic cell death, release of damage-associated molecular patterns (DAMPs), and tumor microenvironment (TME) remodeling; therefore, it will be interesting to investigate the relationship between chemotherapy-induced TME changes and TNBC immunomodulation. In this review, we focus on the immunosuppressive and immunoreactive role of TME in TNBC immunomodulation and the contribution of TME constituents to TNBC subtype classification. Further, we also discuss the role of chemotherapy-induced TME remodeling in modulating TNBC immune response and tumor progression with emphasis on DAMPs-associated molecules including high mobility group box1 (HMGB1), exosomes, and sphingosine-1-phosphate receptor 1 (S1PR1), which may provide us with new clues to explore effective combined treatment options for TNBC.
三阴性乳腺癌（TNBC）是一种异质性疾病，与免疫调节高度相关。众所周知，目前治疗TNBC最有效的方法仍然是化疗。化疗可诱导免疫原性细胞死亡、释放损伤相关分子模式（DAMPs）以及重塑肿瘤微环境（TME）；因此，研究化疗诱导的TME变化与TNBC免疫调节之间的关系将很有意义。在本综述中，我们重点关注TME在TNBC免疫调节中的免疫抑制和免疫反应作用以及TME成分对TNBC亚型分类的贡献。此外，我们还讨论了化疗诱导的TME重塑在调节TNBC免疫反应和肿瘤进展中的作用，重点关注与DAMPs相关的分子，包括高迁移率族蛋白B1（HMGB1）、外泌体和1-磷酸鞘氨醇受体1（S1PR1），这可能为我们探索TNBC有效的联合治疗方案提供新线索。
Zotero 插件